Biogen Pharmachem Industries Ltd

On 05-Dec, Biogen Pharmachem Industries Ltd’s stock price remained unchanged at ₹0.74, yet the broader trend reveals a persistent decline against benchmark indices, reflecting ongoing challenges for the company’s shares.

As of 19-Nov, Biogen Pharmachem Industries Ltd's stock price is Rs 0.78, down 1.27%, with significant underperformance reflected in a 1-week return of -3.70% and a year-to-date decline of 33.90%. The stock is trading below all key moving averages and is close to its 52-week low, indicating reduced investor interest.

Biogen Pharma has experienced significant financial fluctuations, with net sales dropping to zero by March 2025 after a modest increase in previous years, while total expenditures rose sharply and profitability turned negative. Despite these challenges, shareholder funds increased, and cash flow from financing activities remained positive.

Biogen Pharma will announce its results on November 7, 2025.

As of 15-Oct, Biogen Pharmachem Industries Ltd is experiencing a stock price decline to 0.83, down 1.19%, and has underperformed its sector by 2.96%. The stock has been on a downward trend for three consecutive days, with a year-to-date decline of 29.66%, reflecting significant challenges in a generally positive market environment.

As of 07-Oct, Biogen Pharmachem Industries Ltd's stock price has risen to 0.88, up 4.76% today, with a notable 6.02% increase over the past week. Despite recent gains, the stock has declined 25.42% year-to-date, indicating ongoing challenges.

As of 30-Sep, Biogen Pharmachem Industries Ltd's stock price is at 0.83, down 2.35%, with a total decline of 3.49% over the last two days and 6.74% over the past week. Despite recent positive quarterly results, the company struggles with weak long-term fundamentals and diminishing investor participation.

As of 24-Sep, Biogen Pharmachem Industries Ltd is priced at 0.89, with a year-to-date decline of 24.58% and trading below all key moving averages. Despite this negative trend, investor participation has increased, as indicated by a 27.25% rise in delivery volume.

As of 23-Sep, Biogen Pharmachem Industries Ltd is priced at 0.89, with a year-to-date decline of 24.58%, contrasting with the Sensex's gain of 5.07%. Despite a recent increase in investor participation, the stock's performance remains weak, trading below key moving averages and reflecting a bearish trend.

As of 22-Sep, Biogen Pharmachem Industries Ltd is priced at 0.90 with no change, indicating a bearish trend as it trades below all key moving averages. Despite a recent 1.12% weekly increase, the stock has declined 23.73% year-to-date, although there is increased investor interest reflected in a 36.22% rise in delivery volume.

As of 18-Sep, Biogen Pharmachem Industries Ltd's stock price is declining at 0.89, down 1.11%, and underperforming its sector. Despite recent positive quarterly results, the stock shows weak long-term fundamentals and has significantly lagged behind the broader market.

As of 15-Sep, Biogen Pharmachem Industries Ltd's stock price is declining at 0.89, down 2.2%, and has underperformed its sector. Despite recent positive quarterly results, the stock shows weak fundamentals with a low ROE and significant year-to-date losses, indicating ongoing challenges in regaining investor confidence.

As of 10-Sep, Biogen Pharmachem Industries Ltd's stock price is at 0.88, down 1.12%, and has underperformed its sector and the broader market significantly, with a year-to-date decline of 25.42% and a 33.33% drop over the past year. Despite a slight increase in investor participation, the overall trend remains negative.

As of 09-Sep, Biogen Pharmachem Industries Ltd is priced at 0.89, with a short-term underperformance reflected in negative returns and trading below key moving averages. Despite favorable broader market conditions, the stock has declined significantly year-to-date, indicating ongoing challenges.